Regeneron Pharmaceuticals said on Monday that the Covid-19 antibody drug combination it is developing both prevented and treated the disease in rhesus macaques and hamsters, adding to hope that it might work for people.
It said the results matched or exceeded effects recently shown in animal studies of vaccine candidates. The lead researchers said the data suggests the therapy may offer clinical benefit in both prevention and treatment of Covid-19. They also said the animals did not show any signs of increased viral load or worsening of pathology after treatment, an important safety signal that suggests it will not worsen symptoms in humans.